597 related articles for article (PubMed ID: 31580544)
21. Real-world management of hyperkalemia with patiromer among United States Veterans.
Kovesdy CP; Gosmanova EO; Woods SD; Fogli JJ; Rowan CG; Hansen JL; Sauer BC
Postgrad Med; 2020 Mar; 132(2):176-183. PubMed ID: 31971043
[No Abstract] [Full Text] [Related]
22. Cost Consequence Analysis of the Management of Hyperkalemia by Patiromer and Optimization of Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Chronic Kidney Disease Patients in Saudi Arabia.
Shaheen FAM; Meunier A; Altowaijri A; Faadhel TA; Al-Abdulkarim H; AlGabash A; Floros L
Saudi J Kidney Dis Transpl; 2022 Feb; 33(Supplement):S39-S52. PubMed ID: 37102523
[TBL] [Abstract][Full Text] [Related]
23. Associations between serum potassium and adverse clinical outcomes: A systematic literature review.
Palaka E; Grandy S; Darlington O; McEwan P; van Doornewaard A
Int J Clin Pract; 2020 Jan; 74(1):e13421. PubMed ID: 31532067
[TBL] [Abstract][Full Text] [Related]
24. Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.
Weir MR; Bushinsky DA; Benton WW; Woods SD; Mayo MR; Arthur SP; Pitt B; Bakris GL
Am J Med; 2018 May; 131(5):555-564.e3. PubMed ID: 29180023
[TBL] [Abstract][Full Text] [Related]
25. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.
Pitt B; Bakris GL; Bushinsky DA; Garza D; Mayo MR; Stasiv Y; Christ-Schmidt H; Berman L; Weir MR
Eur J Heart Fail; 2015 Oct; 17(10):1057-65. PubMed ID: 26459796
[TBL] [Abstract][Full Text] [Related]
26. Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology.
Bianchi S; Aucella F; De Nicola L; Genovesi S; Paoletti E; Regolisti G
J Nephrol; 2019 Aug; 32(4):499-516. PubMed ID: 31119681
[TBL] [Abstract][Full Text] [Related]
27. Hyperkalemia treatment modalities: A descriptive observational study focused on medication and healthcare resource utilization.
Desai NR; Rowan CG; Alvarez PJ; Fogli J; Toto RD
PLoS One; 2020; 15(1):e0226844. PubMed ID: 31910208
[TBL] [Abstract][Full Text] [Related]
28. Maintaining Renin-Angiotensin-Aldosterone System Inhibitor Treatment with Patiromer in Hyperkalaemic Chronic Kidney Disease Patients: Comparison of a Propensity-Matched Real-World Population with AMETHYST-DN.
Chinnadurai R; Rengarajan S; Budden JJ; Quinn CM; Kalra PA
Am J Nephrol; 2023; 54(9-10):408-415. PubMed ID: 37725919
[TBL] [Abstract][Full Text] [Related]
29. The effect of hyperkalemia and long inter-dialytic interval on morbidity and mortality in patients receiving hemodialysis: a systematic review.
Bem D; Sugrue D; Wilding B; Zile I; Butler K; Booth D; Tafesse E; McEwan P
Ren Fail; 2021 Dec; 43(1):241-254. PubMed ID: 33478329
[TBL] [Abstract][Full Text] [Related]
30. Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry.
Rossignol P; Lainscak M; Crespo-Leiro MG; Laroche C; Piepoli MF; Filippatos G; Rosano GMC; Savarese G; Anker SD; Seferovic PM; Ruschitzka F; Coats AJS; Mebazaa A; McDonagh T; Sahuquillo A; Penco M; Maggioni AP; Lund LH;
Eur J Heart Fail; 2020 Aug; 22(8):1378-1389. PubMed ID: 32243669
[TBL] [Abstract][Full Text] [Related]
31. Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN.
Pitt B; Bakris GL; Weir MR; Freeman MW; Lainscak M; Mayo MR; Garza D; Zawadzki R; Berman L; Bushinsky DA
ESC Heart Fail; 2018 Aug; 5(4):592-602. PubMed ID: 29767459
[TBL] [Abstract][Full Text] [Related]
32. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.
Rosano GMC; Tamargo J; Kjeldsen KP; Lainscak M; Agewall S; Anker SD; Ceconi C; Coats AJS; Drexel H; Filippatos G; Kaski JC; Lund L; Niessner A; Ponikowski P; Savarese G; Schmidt TA; Seferovic P; Wassmann S; Walther T; Lewis BS
Eur Heart J Cardiovasc Pharmacother; 2018 Jul; 4(3):180-188. PubMed ID: 29726985
[TBL] [Abstract][Full Text] [Related]
33. Economic impact of the use of patiromer in chronic kidney disease or heart failure for the treatment of chronic hyperkalemia in Spain.
de Sequera P; Bover R; Ivanova-Markova Y; Ivanova A; González-Domínguez A; Valls M; Campos V
Nefrologia (Engl Ed); 2023; 43(6):721-730. PubMed ID: 38228463
[TBL] [Abstract][Full Text] [Related]
34. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
Weir MR; Rolfe M
Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
[TBL] [Abstract][Full Text] [Related]
35. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
[TBL] [Abstract][Full Text] [Related]
36. Management of Hyperkalemia in Renin-Angiotensin-Aldosterone System Inhibitor: Strategies to Maintain Chronic Kidney Disease Patients with Type II Diabetes on Therapy.
Mahmud HA; Palmer BF
Cardiorenal Med; 2024; 14(1):191-201. PubMed ID: 38513618
[TBL] [Abstract][Full Text] [Related]
37. Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study.
Leon SJ; Whitlock R; Rigatto C; Komenda P; Bohm C; Sucha E; Bota SE; Tuna M; Collister D; Sood M; Tangri N
Am J Kidney Dis; 2022 Aug; 80(2):164-173.e1. PubMed ID: 35085685
[TBL] [Abstract][Full Text] [Related]
38. Prescription of renin-angiotensin-aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care.
Pecoits-Filho R; Fliser D; Tu C; Zee J; Bieber B; Wong MMY; Port F; Combe C; Lopes AA; Reichel H; Narita I; Stengel B; Robinson BM; Massy Z;
J Clin Hypertens (Greenwich); 2019 Jul; 21(7):991-1001. PubMed ID: 31169352
[TBL] [Abstract][Full Text] [Related]
39. [Pharmacology of hyperkalemia].
Rosano GMC
G Ital Cardiol (Rome); 2021 Dec; 22(12 Suppl 1):e8-e12. PubMed ID: 34935774
[TBL] [Abstract][Full Text] [Related]
40. Development of a health economic model to evaluate the potential benefits of optimal serum potassium management in patients with heart failure.
Bakhai A; Palaka E; Linde C; Bennett H; Furuland H; Qin L; McEwan P; Evans M
J Med Econ; 2018 Dec; 21(12):1172-1182. PubMed ID: 30160541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
